Pharma Stock To Consider Dividend On Oct 20, Shares Fall 23.78% From 52-Week High

Mid cap pharmaceuticals sector stock, Laurus Labs Ltd on Friday informed in a regulatory filing that board of directors of the company will hold a meeting on October 20, 2023 to consider and approve un-audited financial results. The company will also consider proposal for payment of interim dividend for FY 2023-24 and fix record date. Last trading price of Laurus Labs share on BSE is Rs 404.10 per share. Laurus Labs shares gave 28% return in last 6-months and fell 20% in last 1-year. Check details below:

Laurus Labs To Consider & Approve Q2 Results, Dividend: The company informed in an exchange filing today, "Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of the Company will be held on Friday, October 20, 2023, inter-alia:to consider and approve the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2023;to consider the proposal for payment of Interim Dividend for FY 2023-24 and fixation of record date for determining the eligibility of shareholders (if approved)."

Laurus Labs Stock Outlook & Return: Last trading price of Laurus Labs share price on BSE is Rs 404.10 per share with intraday gain of 0.67%. The stock's 52-week high price is Rs 530.20 per share and 52-week low price is Rs 279.65 per share, respectively. The company has a market capitalisation of Rs 21,766.88 crore. Laurus Labs stock witnessed a rally of 29% in last 6-months, soared 8% YTD, declined 20% in last 1-year, fell again by 36% in last 2-years, and offered a rally of 23% in last 3-years. Laurus Labs stock surged 392% in last 5-years. Currently, shares of Laurus labs are trading 23.78% down from 52-week high.

Laurus Labs Financials: The company for the quarter ended June 30, 2023 announced a decline of 88.8% YoY in its consolidated net profit at Rs 28.40 crore. It had reported a profit of Rs 252.5 crore in the year-ago period. It declared its revenue at Rs 1181 crore, down 23.2% from 1539 crore in the year ago period.

Laurus Labs About: It works with all the top 10 generic pharmaceutical companies in the world. The company sells its APIs in 56 countries. The company's major focus areas include anti-retroviral, Hepatitis C and Oncology drugs.

Disclaimer:

The stock just highlights the dividend and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.